RT @drdavidliew: Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential
Tweet Content
Mavrilimumab (anti-GM-CSF) in GCA, phase 2
GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying??
PNL induction then enrol+PNL taper
GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62%
Enormous potential, worth exploring!
Cid et al #ACR20 ABSTL06 @RheumNow https://t.co/mq5sTVGbPs
Show on Archive Page
On
Display in Search Results
On